P/E at 31.24 vs Industry's 36.87: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amid Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd stands at 31.24, which is approximately 15.3% lower than the sector average of 36.87. This discount suggests that the market is pricing in either a relative earnings risk or subdued growth expectations compared to its peers. Given the sector’s elevated valuations, driven by innovation and patent pipelines, this gap may reflect concerns specific to the company’s recent performance or outlook. Dr Reddys Laboratories Ltd’s mid-cap market capitalisation of ₹1,00,177.79 crores places it well within the competitive pharmaceutical landscape, yet the valuation gap invites scrutiny — previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating?

Performance Across Timeframes: Mixed Momentum Signals

Examining returns over multiple periods reveals a nuanced performance trajectory. Over the past year, Dr Reddys Laboratories Ltd has declined by 4.69%, underperforming the Sensex’s 3.49% drop. This underperformance extends to the three-month window, where the stock fell 7.88% while the Sensex gained 3.16%. Conversely, the stock has shown resilience in the short term, with a one-week gain of 2.41% compared to the Sensex’s 0.91% loss, and a modest 0.71% rise over the last two trading days. This divergence between short-term strength and medium-term weakness — is this a recovery or a dead-cat bounce? — highlights the challenges in sustaining momentum amid sector headwinds.

Moving Average Configuration: Signs of a Tentative Bounce

The technical setup for Dr Reddys Laboratories Ltd shows the stock trading above its 5-day and 20-day moving averages, signalling short-term buying interest. However, it remains below the 50-day, 100-day, and 200-day moving averages, indicating that the longer-term trend remains bearish. This configuration suggests a recent bounce within a broader downtrend, a pattern often seen when investors test support levels before a decisive move. The stock’s inability to surpass these longer-term averages raises questions about the sustainability of the current rally — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen 29 stocks declare results recently, with 13 reporting positive outcomes, 12 flat, and 4 negative. This distribution indicates a broadly stable sector environment with pockets of strength and weakness. Dr Reddys Laboratories Ltd’s performance, trailing the sector average P/E and showing mixed returns, fits within this context of uneven sector momentum. The sector’s overall resilience contrasts with the stock’s sharper declines over the medium term, suggesting company-specific factors may be influencing investor sentiment.

Rating Reassessment: Previously Hold, Now Reassessed

MarketsMOJO had previously rated Dr Reddys Laboratories Ltd as Hold, with a Mojo Score of 36.0. The rating was updated on 13 Jul 2026, reflecting the latest data on valuation, performance, and technical indicators. This reassessment comes amid the stock’s valuation discount relative to the sector and its mixed performance across timeframes. The updated rating invites investors to consider the implications of the stock’s current positioning — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Longer-Term Returns: Lagging Behind the Sensex

Over extended periods, Dr Reddys Laboratories Ltd has underperformed the Sensex. The three-year return is 3.11% compared to the Sensex’s 18.93%, while the five-year return is 28.90% against the Sensex’s 40.31%. Even over a decade, the stock’s 99.70% gain trails the Sensex’s 176.29%. These figures highlight a persistent challenge in matching broader market returns despite the company’s established presence in the pharmaceutical sector. This long-term underperformance may partly explain the valuation discount and cautious rating stance.

Intraday and Recent Price Action

On 14 Aug 2026, Dr Reddys Laboratories Ltd opened at ₹1,207.45 and traded inline with the sector, closing with a slight decline of 0.48% compared to the Sensex’s 0.38% drop. The stock has recorded gains over the last two days, rising 0.71%, signalling some short-term buying interest. However, the inability to break above longer-term moving averages tempers enthusiasm for a sustained rally.

What the Data Collectively Shows

The valuation discount relative to the sector, combined with mixed performance across timeframes and a tentative technical setup, paints a picture of a stock in transition. While short-term momentum has improved, medium- and long-term returns lag behind broader market benchmarks. The sector’s mixed results further complicate the outlook, with Dr Reddys Laboratories Ltd’s performance reflecting company-specific challenges amid a stable industry backdrop. This complex data landscape raises important questions for investors — what is the current rating for Dr Reddys Laboratories Ltd, and how should investors position themselves?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →